ArticleBMC infectious diseases2026
Clinical analysis of Mycoplasma pneumoniae necrotizing pneumonia in children.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Non-linear associations between inflammatory biomarkers andFrontiers in pediatrics · 2026Article
- Clinical Diagnosis and Treatment of 31 Children withInternational journal of general medicine · 2026Article
- Clinical characteristics and risk factors of necrotizing pneumonia secondary to severe pneumonia in children.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the clinical features and risk factors of Mycoplasma pneumoniae necrotizing pneumonia (MPNP) in children, providing a scientific basis for early diagnosis, effective treatment, and preventive strategies.
methodsA retrospective analysis of 138 children diagnosed with Mycoplasma pneumoniae pneumonia (MPP) admitted to the Children’s Hospital Affiliated to Zhengzhou University from August 2023 to December of the same year was performed. The patient population was divided into the MPNP group (41 cases) and the N-NP (N-Necrotizing pneumonia) group (97 cases) based on the presence or absence of comorbid MPNP. Baseline data, laboratory results, and imaging characteristics were compared. Logistic regression was used to identify risk factors for MPNP, and receiver operating characteristic (ROC) curve analysis was applied to evaluate diagnostic efficacy.
resultsCompared with the N-NP group, children in the MPNP group showed older age, longer hospitalization days, higher fever peak and fever days, and higher rates of chest pain, dyspnea, shortness of breath and combined extrapulmonary complications (all P < 0.05). Laboratory findings showed elevated white blood cells (WBC), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), interleukin−6 (IL−6), serum amyloid A (SAA), serum ferritin (SF), D-dimer (D-D), alanine aminotransferase (ALT), aspartate aminotransferase (AST), immunoglobulin A (IgA), immunoglobulin M (IgM), and lactate dehydrogenase (LDH). While total protein (TP), Albumin (ALB), complement component 4 (C4) levels were significantly lower (P < 0.05). The proportion of children with combined pleural effusion and the percentage of those who underwent fiberoptic bron-choscopic alveolar lavage (FBAL) with alveolar lavage were higher in the MPNP group than in the N-NP group (P < 0.05). Multivariate logistic regression identified age, fever days, D-D, LDH and pleural effusion as independent risk factors for MPNP. ROC curve analysis indicated that children with MPP who were aged > 5.45 years, fever days > 7.5 days, D-D > 0.73 mg/L, LDH > 399 U/L and concurrent pleural effusion predicted MPNP with a sensitivity of 0.878, specificity of 0.876, and area under the curve (AUC) of 0.940 (95%CI: 0.900−0.979).
conclusionAge, fever days, D-D, LDH, and pleural effusion are independent risk factors for MPNP in children. These factors should be closely examined in clinical practice in children with MPP to alert them to the potential risk of NP. Early identification of changes in these risk factors and implementation of timely and effective interventions hold significant clinical value for preventing and controlling the risk of MPP children developing MPNP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.